BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | May 28, 2020

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Inhibiting AFF4 and CDK9, components of the transcription-regulating super elongation complex, could treat diffuse midline glioma. In human diffuse midline glioma cell lines, shRNAs targeting AFF4 or CDK9 or...
BioCentury | May 14, 2020

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

Boehringer is showing itself to be a stealthy but serious player in cutting-edge science with the latest in a series of early-stage deals that come with little notice and plant a flag in an important...
BioCentury | May 6, 2020
Politics, Policy & Law

Bright shines harsh light on America’s COVID-19 preparedness, FDA’s independence

Cronyism has crippled America’s pandemic response, enriching undeserving entrepreneurs and politically potent consultants who siphoned funds that could and should have been used to mount a defense against COVID-19, according to a whistleblower complaint filed...
BioCentury | Apr 28, 2020
Product Development

Blueprint stumbles in GIST race, clearing path for Deciphera

A Phase III miss for Blueprint’s Ayvakit avapritinib in third- and fourth-line GIST likely means the biotech won’t see its NDA approved in the indication, positioning Deciphera to claim a larger share of late-stage settings....
BioCentury | Apr 23, 2020
Product Development

BioCentury expands COVID-19 gateway to connect biotechs, researchers with COVID R&D consortium members

BioCentury has expanded the reach of its COVID-19 Resource Center to enable companies and researchers to submit details of investigational products directly to the pharma companies collaborating within the COVID R&D consortium. The consortium, comprising...
BioCentury | Apr 18, 2020
Product Development

Collaborating to clobber COVID-19

An overlapping set of collaborations is focusing the combined intellectual, logistic and economic resources of the life sciences industry, government, academia and non-profits against SARS-Cov2, the virus that causes COVID-19. The latest and broadest collaboration...
BioCentury | Apr 16, 2020

COVID R&D: Pharmas align behind crowdsourcing solution

Within under a month, a group that started as a mash-up of research heads has morphed into an organized and streamlined collaboration among top pharmaceutical company R&D leaders. Its simple name: COVID R&D. Its goal:...
BioCentury | Apr 2, 2020
Product Development

April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more

Myovant licenses relugolix rights to Gideon for $40M  Myovant Sciences GmbH (NYSE:MYOV) licensed rights of relugolix combination tablets to Gedeon Richter plc (Budapest:RICHTER) in Europe, Russia, Latin America, Australia and New Zealand. Myovant, which retains...
Items per page:
1 - 10 of 4126